Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders

doi:10.1002/mds.10255

PMID: 12465082DOI: 10.1002/mds.10255Dec 5, 2002

Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders

Movement Disorders : Official Journal of the Movement Disorder Society

Jong-Hoon KimYong Sik Kim

Abstract

The metric properties of the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) were examined in 182 subjects treated with antipsychotics. Inter-rater reliability, test-retest reliability, and concurrent validity with other rating scales for EPS were high. Four factors were identified and the optimal diagnostic cut-off scores were obtained. These results suggest that the DIEPSS is a reliable and valid multidimensional rating scale.

References

Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics

Apr 1, 1989·International Clinical Psychopharmacology·M J ReyR Tissot

A rating scale for drug-induced akathisia

May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes

Performance of screening and diagnostic tests. Application of receiver operating characteristic analysis

Jun 1, 1987·Archives of General Psychiatry·J M MurphyG L Klerman

A rating scale for extrapyramidal side effects

Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus

Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs

Dec 1, 1982·Neurology·R E BurkeJ Ilson

Clinical characteristics and predisposing factors in acute drug-induced akathisia

Dec 1, 1994·Archives of General Psychiatry·P Sachdev, J Kruk

The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity

Apr 1, 1993·Acta Psychiatrica Scandinavica·J GerlachD E Casey

Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group

Jan 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·P Martínez-MartínF Bermejo

Current topics in tardive dyskinesia in Japan

Dec 1, 1995·Psychiatry and Clinical Neurosciences·Toshiya Inada, G Yagi

The Maryland Psychiatric Research Center scale and the characterization of involuntary movements

Apr 18, 1997·Psychiatry Research·S L CassadyC A Tamminga

The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curaçao Extrapyramidal Syndromes Study II

Aug 29, 1997·Schizophrenia Research·P N van HartenR S Kahn

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

Feb 16, 1999·Schizophrenia Research·S LeuchtW Kissling

Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia

Jun 1, 1999·Journal of Clinical Psychopharmacology·G MuscettolaP Bollini

Racial variation in antidepressant treatment in a Medicaid population

Mar 1, 2000·The Journal of Clinical Psychiatry·C A MelfiR L Robinson

Olanzapine: extrapyramidal side effects in the elderly

Jun 27, 2000·Australian and New Zealand Journal of Medicine·A S Granger, H C Hanger

The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test-retest reliability and concurrent validity

May 10, 2001·The International Journal of Neuropsychopharmacology·Anton J. M. LoonenArnold E. S. Sijben

Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial

Jul 10, 2001·Psychiatry and Clinical Neurosciences·J IshigookaS Miura

Planning a reproducibility study: how many subjects and how many replicates per subject for an expected width of the 95 per cent confidence interval of the intraclass correlation coefficient

Dec 18, 2001·Statistics in Medicine·B Giraudeau, J Y Mary

Subjective emotional experience and cognitive impairment in drug-induced akathisia

Nov 20, 2002·Comprehensive Psychiatry·Jong-Hoon KimYong Sik Kim

Citations

Drug-induced parkinsonism

Apr 15, 2009·Current Treatment Options in Neurology·Frandy Susatia, Hubert H Fernandez

Breaking the skin barrier

Mar 17, 2004·Advanced Drug Delivery Reviews·Samir Mitragotri

Low-frequency sonophoresis: a review

Mar 17, 2004·Advanced Drug Delivery Reviews·Samir Mitragotri, Joseph Kost

Skin electroporation for transdermal and topical delivery

Mar 17, 2004·Advanced Drug Delivery Reviews·Anne-Rose DenetVéronique Préat

Lipid vesicles and other colloids as drug carriers on the skin

Mar 17, 2004·Advanced Drug Delivery Reviews·Gregor Cevc

Transdermal iontophoresis of insulin: IV. Influence of chemical enhancers

Dec 31, 2003·International Journal of Pharmaceutics·O PillaiR Panchagnula

Sonophoresis in transdermal drug deliverys

Aug 1, 2013·Ultrasonics·Donghee ParkSeunghun Lee

Sonicated transdermal drug transport

Sep 11, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·Amit Joshi, Jaideep Raje

Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs

Apr 25, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Amnon C SintovGalit Levin

Combined chemical and electrical enhancement modulates stratum corneum structure

May 28, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·A M de GraaffJoke A Bouwstra

Electronically facilitated transdermal delivery of human parathyroid hormone (1-34)

Sep 5, 2003·International Journal of Pharmaceutics·Babu M Medi, Jagdish Singh

Iontophoretic R-apomorphine delivery in combination with surfactant pretreatment: in vitro validation studies

Oct 16, 2003·International Journal of Pharmaceutics·Gai Ling LiJoke A Bouwstra

Enhanced iontophoretic delivery of buspirone hydrochloride across human skin using chemical enhancers

Sep 16, 2003·International Journal of Pharmaceutics·Victor M MeidanBozena B Michniak

Novel mechanisms and devices to enable successful transdermal drug delivery

Aug 14, 2001·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·B W Barry

Drug delivery: an odyssey of 100 years

Jul 27, 2001·Current Opinion in Chemical Biology·O PillaiR Panchagnula

Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects

Dec 4, 2003·Clinical Neuropharmacology·Jong-Hoon Kim, Hee-Jung Byun

Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone

Jul 22, 2009·Clinical Neuropharmacology·Jong-Hoon Kim, Min-Jung Kim

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study

May 16, 2013·BMC Psychiatry·Hideaki KatagiriJuan-Carlos Gomez

The relationship between akathisia and subjective tolerability in patients with schizophrenia

Jun 30, 2010·The International Journal of Neuroscience·Jong-Hoon Kim, Hee-Jung Byun

Impairments in executive functioning in patients with remitted and non-remitted schizophrenia

Apr 7, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Da Young YunHee-Yeon Jung

Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol

Sep 19, 2007·Journal of Clinical Pharmacy and Therapeutics·Jong-Hoon Kim, Hee-Jung Byun

Effectiveness of paliperidone extended-release for patients with schizophrenia: focus on subjective improvement

Feb 19, 2013·Human Psychopharmacology·Kyoung-Sae NaSe-Won Lim

Relationship between improvements of subjective well-being and depressive symptoms during acute treatment of schizophrenia with atypical antipsychotics

Mar 4, 2011·Journal of Clinical Pharmacy and Therapeutics·J-H KimM-J Kim

Insight change and its relationship to subjective well-being during acute atypical antipsychotic treatment in schizophrenia

Dec 1, 2010·Journal of Clinical Pharmacy and Therapeutics·Jong-Hoon KimJinyoung Lee

Diminished neurocardiac dynamics associated with antipsychotic-induced extrapyramidal syndrome

Dec 14, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Jong-Hoon KimYong Sik Kim

Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia

Nov 29, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jong-Hoon KimYong Sik Kim

Early treatment response predicted subsequent clinical response in patients with schizophrenia taking paliperidone extended-release

Sep 1, 2015·Psychiatry Research·En-Chi YehChih-Chiang Chiu

Evaluation of the factor structure of symptoms in patients with schizophrenia

Mar 1, 2012·Psychiatry Research·Jong-Hoon KimZang-Hee Cho

The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia

Apr 21, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Sung-Wan KimYoung-Myo Jae

Exploring clinical characteristics of bipolar depression: internal structure of the bipolar depression rating scale

Aug 12, 2009·The Australian and New Zealand Journal of Psychiatry·Jae Seung ChangYong Sik Kim

Rating scales to measure side effects of antipsychotic medication: A systematic review

Jul 11, 2015·Journal of Psychopharmacology·Astrid M van StrienRob J van Marum

Antipsychotic medication side effect assessment tools: A systematic review

Oct 21, 2015·The Australian and New Zealand Journal of Psychiatry·Norman Jay StomskiAmanda Meyer

Factors inducing falling in schizophrenia patients

Mar 31, 2017·Journal of Physical Therapy Science·Yoko TsujiFumio Hirao

Multidimensional sensory phenomena in antipsychotic-induced akathisia

Nov 13, 2004·Journal of Clinical Psychopharmacology·Jong-Hoon KimYong Sik Kim

Relationship between subjective experiences and psychopathological dimensions in schizophrenia

Oct 12, 2010·The Australian and New Zealand Journal of Psychiatry·Jong-Hoon KimJinyoung Lee

Antipsychotic-Induced Pisa Syndrome: A 2-Year Follow-up Study

Mar 14, 2018·Clinical Neuropharmacology·Yen-Feng Lee

Antipsychotic combinations for schizophrenia

Jun 29, 2017·The Cochrane Database of Systematic Reviews·Javier Ortiz-OrendainClive E Adams

Physical Activity of Patients with Chronic Schizophrenia and Related Clinical Factors

Jul 4, 2018·Psychiatry Investigation·Sook-Hyun LeeSeunghyong Ryu

Reliable and quantitative SERS detection of dopamine levels in human blood plasma using a plasmonic Au/Ag nanocluster substrate

Nov 28, 2018·Nanoscale·Viet-Duc PhungSang-Wha Lee

Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism

Feb 11, 2009·Human Psychopharmacology·Jong-Hoon Kim, Hee-Jung Byun

Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research

Jan 16, 2010·Journal of Clinical Psychopharmacology·Wilma KnolRob J van Marum

Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial

Jul 28, 2010·Clinical Neuropharmacology·Jaewon YangSeung-Hyun Kim

A Neural Signature of Parkinsonism in Patients With Schizophrenia Spectrum Disorders: A Multimodal MRI Study Using Parallel ICA

Mar 13, 2020·Schizophrenia Bulletin·Robert C WolfDusan Hirjak

Dyskinesia is most centrally situated in an estimated network of extrapyramidal syndrome in Asian patients with schizophrenia: findings from research on Asian psychotropic prescription patterns for antipsychotics

Jun 26, 2020·Nordic Journal of Psychiatry·Seon-Cheol ParkToshiya Inada

Prevalence of Extrapyramidal Symptoms in Cancer Patients Referred to Palliative Care: A Multicenter Observational Study (JORTC PAL12)

Sep 18, 2020·The American Journal of Hospice & Palliative Care·Hiroto IshikiSatoru Iwase

Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study

Jun 11, 2018·International Journal of Bipolar Disorders·Joseph R CalabreseHiroaki Kawasaki

Cannabis use correlates with aggressive behavior and long-acting injectable antipsychotic treatment in Asian patients with schizophrenia

Jun 27, 2019·Nordic Journal of Psychiatry·Seon-Cheol ParkYong Chon Park

Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) Serbian Language version: Inter-rater and Test-retest Reliability

Aug 16, 2017·Scientific Reports·Ami PeljtoToshiya Inada

Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study

Jul 21, 2016·Clinical Neuropharmacology·Hui Woo YoonByung Ook Lee

A missed case of lurasidone induced laryngospasm: A case study and overview of extrapyramidal symptom identification and treatment

Jul 15, 2020·International Journal of Psychiatry in Medicine·Deirdre Caffrey, Gillian L Sowden

Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia.

Jul 9, 2020·Journal of Clinical Psychopharmacology·Stanley N CaroffE Cabrina Campbell

Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study

Nov 28, 2018·Journal of Pharmaceutical Health Care and Sciences·Takahiro ItoIkuko Yano

Drug-Induced Extrapyramidal Symptoms Scale of the Norwegian version: inter-rater and test-retest reliability

Sep 19, 2019·Nordic Journal of Psychiatry·Bernhard WeidleToshiya Inada

Related Concepts

Lenticulostriate Disorders

Dyskinesia, Medication-Induced

Neurologic Examination

Schizophrenia

Antipsychotic Effect

Intraobserver Variation

Pseudoakathisia

Ramsay Hunt Paralysis Syndrome

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders

Abstract

References

Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics

A rating scale for drug-induced akathisia

Performance of screening and diagnostic tests. Application of receiver operating characteristic analysis

A rating scale for extrapyramidal side effects

Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs

Clinical characteristics and predisposing factors in acute drug-induced akathisia

The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity

Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group

Current topics in tardive dyskinesia in Japan

The Maryland Psychiatric Research Center scale and the characterization of involuntary movements

The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curaçao Extrapyramidal Syndromes Study II

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia

Racial variation in antidepressant treatment in a Medicaid population

Olanzapine: extrapyramidal side effects in the elderly

The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test-retest reliability and concurrent validity

Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial

Planning a reproducibility study: how many subjects and how many replicates per subject for an expected width of the 95 per cent confidence interval of the intraclass correlation coefficient

Subjective emotional experience and cognitive impairment in drug-induced akathisia

Citations

Drug-induced parkinsonism

Breaking the skin barrier

Low-frequency sonophoresis: a review

Skin electroporation for transdermal and topical delivery

Lipid vesicles and other colloids as drug carriers on the skin

Transdermal iontophoresis of insulin: IV. Influence of chemical enhancers

Sonophoresis in transdermal drug deliverys

Sonicated transdermal drug transport

Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs

Combined chemical and electrical enhancement modulates stratum corneum structure

Electronically facilitated transdermal delivery of human parathyroid hormone (1-34)

Iontophoretic R-apomorphine delivery in combination with surfactant pretreatment: in vitro validation studies

Enhanced iontophoretic delivery of buspirone hydrochloride across human skin using chemical enhancers

Novel mechanisms and devices to enable successful transdermal drug delivery

Drug delivery: an odyssey of 100 years

Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects

Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study

The relationship between akathisia and subjective tolerability in patients with schizophrenia

Impairments in executive functioning in patients with remitted and non-remitted schizophrenia

Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol

Effectiveness of paliperidone extended-release for patients with schizophrenia: focus on subjective improvement

Relationship between improvements of subjective well-being and depressive symptoms during acute treatment of schizophrenia with atypical antipsychotics

Insight change and its relationship to subjective well-being during acute atypical antipsychotic treatment in schizophrenia

Diminished neurocardiac dynamics associated with antipsychotic-induced extrapyramidal syndrome

Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia

Early treatment response predicted subsequent clinical response in patients with schizophrenia taking paliperidone extended-release

Evaluation of the factor structure of symptoms in patients with schizophrenia

The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia

Exploring clinical characteristics of bipolar depression: internal structure of the bipolar depression rating scale

Rating scales to measure side effects of antipsychotic medication: A systematic review

Antipsychotic medication side effect assessment tools: A systematic review

Factors inducing falling in schizophrenia patients

Multidimensional sensory phenomena in antipsychotic-induced akathisia

Relationship between subjective experiences and psychopathological dimensions in schizophrenia

Antipsychotic-Induced Pisa Syndrome: A 2-Year Follow-up Study

Antipsychotic combinations for schizophrenia

Physical Activity of Patients with Chronic Schizophrenia and Related Clinical Factors

Reliable and quantitative SERS detection of dopamine levels in human blood plasma using a plasmonic Au/Ag nanocluster substrate

Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism

Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research

Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial

A Neural Signature of Parkinsonism in Patients With Schizophrenia Spectrum Disorders: A Multimodal MRI Study Using Parallel ICA

Dyskinesia is most centrally situated in an estimated network of extrapyramidal syndrome in Asian patients with schizophrenia: findings from research on Asian psychotropic prescription patterns for antipsychotics

Prevalence of Extrapyramidal Symptoms in Cancer Patients Referred to Palliative Care: A Multicenter Observational Study (JORTC PAL12)

Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study

Cannabis use correlates with aggressive behavior and long-acting injectable antipsychotic treatment in Asian patients with schizophrenia

Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) Serbian Language version: Inter-rater and Test-retest Reliability

Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study

A missed case of lurasidone induced laryngospasm: A case study and overview of extrapyramidal symptom identification and treatment

Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia.

Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study

Drug-Induced Extrapyramidal Symptoms Scale of the Norwegian version: inter-rater and test-retest reliability

Related Concepts

Related Feeds

Antipsychotic Drugs

Related Papers